SCT Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets

News   Aug 12, 2013

 
SCT Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
 
 
 

RELATED ARTICLES

The Salk Institute and Indivumed: Advancing Global Cancer Research Through Partnership

News

The Salk Institute and Indivumed GmbH, a world leading cancer research company today announce a multi-year strategic alliance to secure, preserve and analyze human cancer tissue and annotated clinical data from consenting patients around the world, enabling the most cutting-edge basic and translational research in cancer.

READ MORE

Scleroderma Study Offers New Hope For Sufferers

News

An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study found. The approach could represent the first new treatment to improve survival in patients with severe scleroderma in more than four decades.

READ MORE

Dietary Fat Metabolism May Promote Metastasis

News

A new study has highlighted links between dietary fat and prostate cancer, suggesting a high-fat Western diet may encourage tumour metastasis.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE